Such activation of HER3 signaling by EGFR and HER2 is observed in lung and breast cancers, and combinatorial targeting of HER3 along with EGFR and HER2 via antibodies has been validated as a means to increase the efficacy of therapeutic intervention and delay or prevent the onset of acquired resistance [13–15]. Here, ERBB2 is linked to breast carcinoma.